Nuclear Medicine Department, Royal Brompton Hospital, London, UK.
Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):160-4. doi: 10.1007/s00259-011-1923-9. Epub 2011 Sep 6.
This is the second of a series of surveys designed to assess myocardial perfusion scintigraphy (MPS) practice in Europe.
Data were collected from 258 centres in 18 countries. The number of MPS studies per million population (pmp) was estimated assuming that the nonresponding centres performed either no studies (lower estimate) or the same number as the responding centres (upper estimate).
The responding centres served 24% of the population of their countries. The total number of noncardiac nuclear medicine studies was between 2,160 and 8,000 studies pmp. The total number of MPS studies was between 529 and 2,293 pmp. The median number of MPS studies per centre was 571 per year with 57% performing fewer than 500 studies per year and 23% of centres performing fewer than 250 studies per year. There was significant variation between countries, with higher numbers of MPS studies (lower limit of estimate above the mid-range of all countries combined) in Austria, Denmark, Hungary, Portugal and Slovenia, and lower numbers (upper limit of estimate below the mid-range of all countries) in Finland, Norway, Spain and Switzerland. The ratio of MPS to coronary angiography to revascularization procedures was 0.9 to 2.2 to 1. Pharmacological stress was used in 57% and technetium-99m-labelled tracers in 88% of studies. ECG gating was performed in 74% of studies and attenuation correction in 22%.
MPS utilization in Europe remains low compared with coronary angiography although there has been a 21% increase in the number of studies pmp in centres that reported in both 2005 and 2007. Pharmacological agents continue to be the predominant form of stress. Despite the widespread use of technetium-99m-labelled tracers, ECG gating is not universally performed. As in the 2005 survey, imaging aids such as attenuation and motion correction and prone imaging are not commonly used.
这是一系列旨在评估欧洲心肌灌注闪烁照相术（MPS）实践的调查中的第二项。
数据来自 18 个国家的 258 个中心。假设未回复的中心未进行任何研究（较低估计值）或与回复中心进行相同数量的研究（较高估计值），则估计了每百万人口的 MPS 研究数量（pmp）。
回复中心服务于其所在国家 24%的人口。非心脏核医学研究的总数为 2160 至 8000 次 pmp。MPS 研究的总数为 529 至 2293 pmp。中心每年 MPS 研究的中位数为 571 次，其中 57%的中心每年进行的研究少于 500 次，23%的中心每年进行的研究少于 250 次。各国之间存在显著差异，奥地利、丹麦、匈牙利、葡萄牙和斯洛文尼亚的 MPS 研究数量较高（估计值上限高于所有国家的中值范围），芬兰、挪威、西班牙和瑞士的 MPS 研究数量较低（估计值上限低于所有国家的中值范围）。MPS 与冠状动脉造影和血运重建程序的比例为 0.9 比 2.2 比 1。57%的研究使用药物负荷，88%的研究使用锝-99m 标记示踪剂。74%的研究进行心电图门控，22%的研究进行衰减校正。
与冠状动脉造影相比，欧洲的 MPS 使用率仍然较低，尽管在 2005 年和 2007 年报告的中心中，pmp 的研究数量增加了 21%。药物负荷仍然是主要的应激形式。尽管广泛使用锝-99m 标记示踪剂，但并非普遍进行心电图门控。与 2005 年的调查一样，成像辅助设备（如衰减和运动校正以及俯卧位成像）并不常用。
